The overall goal of the Pharmacology and Analytical Center Facility is to provide the broad base of sophistical analytical equipment and expertise in pharmacology and medicinal chemistry required for preclinical and clinical investigations of anti-cancer drugs and related therapies. This goal will be accomplished by focusing on three aims. First, the Pharmacology and Analytical Center Facility will enable expanded analytical support for basic and clinical scientists at The University of Texas M.D. Anderson Cancer Center. This support will include access to instruments for nuclear magnetic resonance (NMR), liquid chromatography (LC)/mass spectrometry (MS), gas chromatography (GC), GC/MS, and high- performance liquid chromatography (HPLC). Support will also include assistance with the verification of structural identify, purification, and determination of stability of drugs and drug metabolites, as well as assistance with developing assays, solving proof-of-identity problems, and developing validation procedures. Second, scientists running the Pharmacology and Analytical Center Facility will provide a resource for investigators seeking pharmacokinetic and pharmacodynamic information on specific compounds and knowledge off how to best use such information for optimal protocol design, dose adjustments to increase efficacy or decrease toxicity, and similar clinical problems. Finally, the Pharmacology and Analytical Center Facility will provide a pharmacology resource for information about and techniques for studying nucleic acid components, such as bases, nucleosides, nucleotides, and oligonucleotides. This services will also include quantitation of the radioactivity associated with proteins, and Betascope and radiometric flow analytical instrumentation will be available. The analytical instruments of the Pharmacology and Analytical Center Facility are conveniently housed on the same (seventh) floor of M.D. Anderson Cancer Center in laboratories run by Director Robert Newman and co-directors William Plunkett, Timothy Madden, and David Farquhar. The equipment and analytical support to be provided by the facility are deemed critical for the success of many of the disease site- and them-specific programs proposed in this application. Formation of the Pharmacology and Analytical Center Facility will augment the ability of M.D. Anderson investigators to collaborate on studies involving pharmacologic analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-25
Application #
6334927
Study Section
Project Start
2000-07-18
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
25
Fiscal Year
2000
Total Cost
$332,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Boddu, Prajwal; Oviedo, Sergio Pina; Rausch, Caitlin R et al. (2018) PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 59:1486-1489
Assi, Rita; Garcia-Manero, Guillermo; Ravandi, Farhad et al. (2018) Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124:4192-4201
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Luo, Yangkun; Xu, Yujin; Liao, Zhongxing et al. (2018) Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis? Acta Oncol :1-7
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Liu, Yihua; Weber, Zachary; San Lucas, F Anthony et al. (2018) Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. Gynecol Oncol 151:243-249
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Jensen, Garrett; Tao, Randa; Eng, Cathy et al. (2018) Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol 3:595-600
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Boddu, Prajwal; Borthakur, Gautam; Koneru, Mythili et al. (2018) Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369

Showing the most recent 10 out of 12418 publications